Roy M Gulick

Roy M Gulick is the Rochelle Belfer Professor in Medicine at Weill Cornell Medical College, where he has served since 2016. He is a leading expert in HIV treatment and prevention, with a focus on antiretroviral therapy, pharmacogenetics, and clinical trials.

• M.P.H., Harvard School of Public Health (1993)
• M.D., Columbia University College of Physicians and Surgeons (1986)
• B.A., The Johns Hopkins University (1982)

His research spans HIV virology, pre-exposure prophylaxis (PrEP), long-acting therapies, and the intersection of HIV with public health crises like the COVID-19 pandemic. He has led major trials such as HPTN 069/ACTG A5305 and HPTN 083, contributing to guidelines for HIV management and prevention.

His recent publications emphasize long-acting HIV treatments, adherence monitoring, and the application of polygenic risk scores to predict treatment outcomes. Articles highlight collaborations with the NIH RECOVER Program and the National Institutes of Health COVID-19 Treatment Guidelines Panel.

Gulick's work is supported by grants from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Child Health & Human Development (NICHD). He serves as Principal Investigator for the AIDS Clinical Trials Group (ACTG) and co-leads initiatives like HPTN 083.

He collaborates with institutions such as the Northeast/Caribbean AIDS Education and Training Centers and Rutgers New Jersey Medical School. His advisory roles include UpToDate, Inc. and Ashfield Healthcare.